A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li
A phase 1/2 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) is a phase 1/2 interventional study registered as NCT04524871 by Hoffmann-La Roche, with 518 participants planned, started 2020-11-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120. Conditions listed: Advanced Liver Cancers. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Tiragolumab, Atezolizumab, Roche / Genentech, Bevacizumab.
- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Tiragolumab, Atezolizumab.
- TrialA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Shares ADG126, Bevacizumab.